Saturday, May 24, 2014

065 - Active Immunization Against Whooping Cough: Interim Report of the Cleveland Experience

Apparently there was a lot of interest in a vaccine against whooping cough around this time. Makes sense; it sounded pretty serious. People had recently discovered that when growing the pertussis bacteria in the lab, they started off with smooth-looking colonies that were virulent, which over time sometimes got more rough and less harmful. Some graded these from Phase I (smoothest, most virulent) to Phase IV (roughest, least virulent). Sauer and others thought the Phase I would make the best vaccine.

Studying vaccines of pertussis was tricky: the way the vaccine was made could influence things, obviously (as this study itself seems to show), and diagnosing the disease could be uncertain, and they weren’t even sure if having the bacteria in your body was even enough to make you sick; some might have the bacteria and not be sick, though there seemed to be some evidence against that idea.

Based on previous experience, James Doull, Gerald Shibley, and Joseph McClelland decided that a study of 200-300 children in each group (vaccinated and unvaccinated) could detect a difference in pertussis cases decently. But just to be safe, they decided to go with a higher number, around 500 per group.1

They recruited these children at health stations in Cleveland that gave out free milk. The requirements were that the children must not have had pertussis before, and needed to have an older sibling who also had not had pertussis (to increase the likelihood of exposure), and had to be between 6-15 months old.

They started out planning to give every other child the vaccine they made, but a lot of parents refused to let their children be vaccinated, so they ended up counting some refusers as controls instead. So there ended up being 483 vaccinated (most with all three doses, a few with only one or two), 247 selected as controls, and 249 that refused. So almost 1000 total.

The vaccine was made with 5 recently isolated (and thus smooth and virulent) strains of bacteria, grown on agar, scraped off, washed with distilled water, and suspended in saline with 0.5% phenol. Standardized doses were given once a week for three weeks, subcutaneously in the buttocks. Sounds like fun.

They noticed some reactions to it, but not many. Some had a slight fever on the same day, or a local reaction lasting up to 3 days. It was claimed that 3 had convulsions, one of which was observed by a nurse.

After inoculation, the authors kept tabs on their subjects, sometimes sending someone to check on the families. If any reported a case, an epidemiologist or pediatrician obtained records and tests to confirm.

The distribution of race and sex in the groups seemed pretty even, though there might’ve been more white people refusing the vaccine than minorities. The age distribution was fairly even though too.

Ok, results: not great. 61 out of 483 vaccinated got whooping cough, or 12.6%. Of those not vaccinated, either from randomness or refusal, 71 of 496 (14.3%) got whooping cough. So at most, the vaccine was 11.6% effective, or prevented the disease in 11.6% of those who would’ve gotten it. Pretty awful.

They did mention that some thought the vaccinated cases might’ve been milder, but it seemed like a rather subjective judgment:
"The opinion of physicians who have seen representative attacks in both groups is that those in the inoculated have been milder. This is a difficult question to settle. There has been only 1 death, and that in a control child."
Overall, seems like pretty clear negative results. It wasn’t a great study (no placebo, no blinding, not even very good randomization), but usually one expects those problems to give more positive results, not less positive. So it’s somewhat interesting, considering the positive results others had observed with similar vaccines around that time.

Some people in later articles had some ideas about what the difference might be:
"In three field studies...favorable results were reported. In another very thorough study [this one] in which the method of preparation of vaccine was slightly different unequivocal evidence of immunization was not obtained."2
"The Cleveland vaccine [this study] was also a Phase I vaccine [freshly isolated organisms] containing 10 billion organisms per ml., but in its preparation the organisms had been washed once with distilled water, while the Michigan vaccine [showing a positive result] had been washed once with saline."3
"These varying estimates of vaccine performance had at least two possible explanations. They might have reflected either differing manufacturing processes, or variations in the methodological rigour of the studies."4
"In his pertussis studies, Doull relied on alternation, which in his view was sufficient to prevent bias in selecting which children would receive the vaccine. However, the actual allocations departed from this 'ideal' somewhat: in one recruiting location, Doull used children whose parents refused inoculation as the controls, while at a later point in the study, he assigned the vaccine in a 2:1 ratio, with every third child serving as a control."5

Citations:
1.  Doull, J. A., Shibley, G. S. & McClelland, J. E. Active Immunization Against Whooping Cough: Interim Report of the Cleveland Experience. Am J Public Health Nations Health 26, 1097 (1936).
2.  Singer-Brooks, C. & Miller, J. J. The Opsono-Cytophagic Test in Children with Pertussis and in Children Vaccinated with H. pertussis Antigens. J Clin Invest 16, 749–761 (1937).
3.  Perkins, J. E., Stebbins, E. L., Silverman, H. F., Lembcke, P. A. & Blum, B. M. Field Study of the Prophylactic Value of Pertussis Vaccine. Am J Public Health Nations Health 32, 63–72 (1942).
5.  Marks, H. M. James Angus Doull and the well-controlled common cold. J R Soc Med 101, 517–519 (2008).

Monday, May 19, 2014

About Me - Who is this guy anyway?

I'm a PhD student studying microbiology, though not specifically the health-related kind at this point. I don't claim expertise in vaccines or immunology or toxicology or any of that, so I don't want you to accept what I say because of who is saying it; I try to reference my claims well and make it accessible so you can check my work and make sure I get it right.

The reason I started this blog is that I had always thought vaccines were pretty neat, giving people immunity to diseases without having to actually go through the disease process, but some people think this is not a good thing. So I decided to do a thorough investigation of vaccines: their history, safety, and effectiveness, to make sure I have good reasons for what I believe, or change my belief if it turns out I'm wrong. That's how science works. Not that it'll be the final word on the subject for anyone but me, I expect. I started this blog for my own benefit, to try to motivate me to keep up work at this project, but it's public, so if anyone else benefits too, that's great.

Other than that... I like making science interesting to people, especially microbiology, so I have a podcast (BacterioFiles). I like growing my own food (gardening, chickens). I like fermenting my food too (yay microbes!): sauerkraut, pickles, sourdough, kombucha, yogurt... all very tasty, and if there's any health benefit that's good too, though I'm not completely convinced.

So overall... I enjoy nature, health, and science.

Conflicts of interest: I don't work for a vaccine manufacturer and don't have any friends or family who benefit financially from vaccines. I think I may have a few stocks in pharmaceutical companies that were given to me as a child, but I don't know how much they're worth. That's it. But like I said, regardless, don't take my word for anything I say; check my work.

Sunday, May 18, 2014

064 - Prophylactic pertussis immunization

Today's study is another test of whooping cough vaccines. Sauer's was the popular one at this time, showing 92% efficacy in some studies, but a Lucy Mishulow had created one that used a stock strain of pertussis instead of needing to isolate a new one with every outbreak, as the Sauer version called for. Also, it could be grown on animal blood instead of human blood. This made it more potentially useful.

So Eli Shorr selected preschool children with known histories of illness to vaccine or keep as controls. He tried to divide families up evenly between vaccinated and controls, to make things as equivalent as possible. Half the subjects attended the same nursery school.

They compared different methods of inoculation: intramuscular, intracutaneous, and subcutaneous. After, they looked at levels of agglutinins in the blood as a measure of antibody response.

In order to compare, they gave a few children the Sauer vaccine, and some of the controls got an injection of sterile diluted milk as a placebo.

They found that about 36% of the subjects were definitely exposed to pertussis over the next 30 months; probably more that they didn't notice. 16% of those receiving Mishulow's vaccine got pertussis, 10 out of 63, though 6 of the 10 were very mild cases (no whooping even), and also 6 of the 10 got sick within the period Sauer thought might be too soon for immunity to develop, and 4 of them had smaller doses of vaccine too. So it might be said that only 10% of well-vaccinated subjects got sick.

With the Sauer vaccine, 1 of 11 (9%) got sick, but that one had gotten a low dose too.

Whereas with controls, 26 of 72 (36%) got pertussis. Big difference. And they weren't even observed for as long a period.

In terms of inoculation route, intracutaneous was abandoned early because it was difficult to give an adequate dose and reactions to it were overly severe. Reactions to the other routes were never severe; most just had slight tenderness, some had redness or a low fever for a day or two.

The antibody measurements were as expected, pretty high soon after vaccination but none or very low in unvaccinated group. Levels fell after 2-3 months, but it wasn't clear if that meant immunity went away or anything.

So overall, it seemed like Mishulow's vaccine was pretty good, but it was too small a study to compare to Sauer's very well. Googling "Lucy Mishulow" doesn't bring up many results, so I wonder if the vaccine turned out badly somehow, such that this vaccine researcher got mostly lost to the sands of time somehow. Maybe I'll find out later.

Citation: Shorr, E. Y. Prophylactic pertussis immunization. The Journal of Pediatrics 9, 49–55 (1936).

Saturday, May 10, 2014

063 - Susceptibility and immunity: In relation to vaccination in acute anterior poliomyelitis

As discussed before, John Kolmer's version of a polio vaccine failed the test of safety (048). But that doesn't mean we can't learn anything from him, especially about polio in general. Keeping in mind that he did have a conflict of interest, being a vaccine inventor.

In this article, he speculated that polio would make a good target for vaccine prevention, because 1) it was scary, killing at least 73 in 1000 victims and even up to 43 in 100 in some epidemics, and paralyzing another 25-45%; 2) those who survived seemed to be immune and have anti-polio antibodies throughout life.

He also noted that, although infants under 1 year old seemed to have temporary immunity transferred from their mothers, this faded over time, such that a large proportion of children under 10 were susceptible to the disease. So they'd be good candidates for a vaccine.

He discusses a bunch of other stuff, especially his own vaccine-making efforts, but nothing that seems particularly important.

Citation: Kolmer, J. A. Susceptibility and immunity: In relation to vaccination in acute anterior poliomyelitis. JAMA 105, 1956–1963 (1935).

Saturday, May 3, 2014

062 - Virus—antivirus mixtures in smallpox vaccination

Immunization against smallpox using vaccinia or cowpox virus was not always a harmless procedure (though of course better than getting smallpox itself!): it often produced an unsightly scar at the inoculation site, and sometimes at other sites; a general reaction could be problematic, especially in infants; and at worst, post-vaccinal encephalitis.

So people were trying to find a safer way of doing it. One way that seemed successful in animal studies was mixing the vaccinia virus with serum containing anti-vaccinia antibodies and inoculating that. Similar to how people vaccinated against diphtheria toxin using mixtures of toxin and antitoxin antibodies. Some found that such antibodies could prevent potent vaccinia from producing generalized lesions in rabbits, without reducing immunity too much, and others found that completely neutralized virus could still induce immunity when introduced nasally.

So Frisch wanted to find out if this could work in human children, and how. So he took two groups of children, 39 in one and 47 in the other, and immunized them using mixtures of virus and antibody-containing serum, in various proportions between 3:1 and 1:20 virus:serum. The first group got serum from children that had been vaccinated 5 years before, and the second from children vaccinated only 4 weeks before. After a while, he revaccinated some of them with pure virus to see if they seemed immune to it.

In the first inoculation, the virus mixed with 5-year serum seemed much more potent than that in 4-week serum, causing typical vaccinia reactions in almost everyone getting a mix of as low as 11% virus. That mixed with 4-week serum didn't consistently cause reactions unless the ratio was 3:1 virus to serum.

Did either of these induce immunity despite lack of reaction? The answer seemed to be no; most of the revaccinated children showed a typical vaccinia infection, unless they had received enough undilute virus to cause a reaction the first time. And waiting up to 9 months for immunity to develop didn't seem to change anything.

So antibodies against vaccinia seem to inhibit all its effects, both reactions and immunity. Too bad. Well, even if the children had shown immunity, I'm not sure how much it would mean, since it'd be immunity to vaccinia rather than to smallpox, though there would probably be at least some overlap.

The other interesting thing is that it showed that levels of antibodies from vaccination did decrease over 5 years, so that the serum was less potent in neutralizing the virus. Did this mean the 5-year serum donors were no longer immune? Can't tell from this study: it might not take very much to protect against infection. It just shows their levels were relatively lower than the others, not necessarily inadequate.

Citation: Frisch, I. A. Virus—antivirus mixtures in smallpox vaccination. Am J Dis Child 49, 894–899 (1935).